and great access to deal flow
Before founding ATAI Life Sciences to address the mental healthcare crisis, Christian co-founded Ribopharma which merged with US peer Alnylam in 2003 and subsequently went public. Since then, Christian has created, co-founded and invested in numerous successful companies, has raised approximately USD 2 billion for his portfolio companies and has been involved in more than 40 successful IPO- and M&A-transactions either as an entrepreneur, investor, banker, or advisor.
Florian is the co-founder and Chief Executive Officer of ATAI Life Sciences, a global biotech company builder with the vision of ultimately ending mental health disorders. Prior to joining ATAI, Florian served as Managing Director of Springlane, Germany’s leading online kitchen appliance retailer. Florian’s experiences seeing his friends and loved ones failed by the mental health system inspired him to join the movement to transform the way we discover and develop novel neuropsychiatric therapeutics.
Srinivas Rao, MD, PhD
Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG. Dr. Rao has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to ATAI, Dr. Rao held the titles of Chief Scientific, Medical, or Executive Officer at companies ranging from venture backed startups to vertically-integrated, publicly traded pharmaceutical companies.
Matthias Luz, MD
Dr. Luz joined ATAI Life Sciences to help transform the mental health space and work towards a cure for core neuropsychiatric disorders. Prior to joining ATAI, Dr. Luz served in various C-suite roles at numerous pharmaceutical companies such as Aventis, where he led the team that brought Refludan® (lepirudin), the first therapeutic for heparin-induced thrombocytopenia, to market worldwide. Dr. Luz also serves as Chief Medical Officer of ATAI platform-company DemeRx.
Dr. Greg Bates, a veterinarian by training, joined ATAI Life Sciences as Regulatory Affairs Lead in June 2019. He is a pharmaceutical executive with more than 30 years of international industry experience in regulatory affairs encompassing the regulation of veterinary and human pharmaceuticals, biologics, and live biotherapeutic products (LBP), as well as devices and dietary supplements.
Danny is the Lead of Business Development at ATAI Life Sciences; he primarily focuses on sourcing new investment opportunities in the mental health space. Danny has spent 15+ years in neuroscience and is passionate about identifying innovative therapies with the potential to impact the treatment of mental health disorders.
David Keene is veteran of the both the video game and digital therapeutics industries. Within the field of digital therapeutics Mr. Keene co-founded Dthera Sciences. The product he developed at Dthera was granted Breakthrough Device designation by the FDA and was named among the “Top 4 Best Designed Products in Digital Health of 2019” by Rock Health, alongside Apple Watch and Apple Health Records.
Michael Cunniffe is Lead of Finance at ATAI Life Sciences. Prior to joining ATAI, Michael worked in senior finance roles for early stage gene-therapy and listed vaccines companies. These roles covered corporate strategy, forecasting and planning, controlling, operating models and fund raising focused on the US and European healthcare markets.
Roman Dahl is Lead of Operations and Data at ATAI Life Sciences. Prior to joining ATAI, Roman was responsible for Strategy & Operations at DeepMind Health and subsequently Google Health where he led product portfolio strategy for imaging diagnostics and provider solutions. Roman brings almost a decade of experience in strategy & operations across healthcare, artificial intelligence, media and online advertising.
Glenn Short, PhD
Glenn Short is Lead of Early Development at ATAI Life Sciences where he works with ATAI’s portfolio companies to advance discovery, preclinical and early clinical stage assets into clinical development. Dr. Short has 15 years of industry and research experience and has been involved in numerous programs that leverage cutting edge biotechnologies to develop new therapies to address unmet medical needs in oncology, immunology, neurological disease and pain.
Galyna Pidpruzhnykova, PhD
Galyna is Innovation strategy Manager at ATAI Life Sciences; her focus is development and execution of ATAI’s innovation strategy and establishment of new collaborations. Galyna is a Neurobiologist with 10 years of academic experience, 2 years of biopharma R&D strategy consulting and leadership positions in non-profit organizations. She is driven by combining her passion for neuroscience and mental health with the real outcomes.
Aaron serves as Senior General Counsel and also supports fundraising and investor relations activities at ATAI. He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. Prior to joining ATAI, from 2013 – 2017, he was an investment banker at Credit Suisse within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies.
Ana Zarzosa, PhD
Ana holds a doctorate in Life Sciences from the International Max Planck Research School. She is an experienced Yoga and Mindfulness instructor, and has supported smooth communication and a high-performance team environment since joining ATAI. Prior to joining ATAI, Ana worked in business operations and development across different industries, establishing processes and improving organizational structure and growth.
Juliane, M.Sc. in Publishing, is the Human Resource Manager at ATAI. Juliane has gained 5 years of experience in different branches and companies located in Zurich, Berlin, London, SF. Prior to ATAI she has been working in the Talent Acquisition department of a fast growing med-tech company. Prior to that she has been accompanying the scale-up Beekeeper, an internal communications platform in Zurich, from 25 to 120 employees.
Simon became interested in psychology and neuropsychiatry at a young age, and soon realized the lack of innovation in the space and the various shortcomings of the current medical system. Committed to providing disruptive solutions, Simon joined ATAI Life Sciences as its first employee and helped build the company from the ground up. Now, he is mainly focused on venture building.
Philipp Schreiber is an Associate at ATAI Life Sciences. Beyond supporting ATAI, Philipp is responsible for portfolio development at Apeiron Investment Group, the family office of Christian Angermayer, where he mainly focuses on corporate strategy and deal execution for the groups biotech platform companies. Philipp brings experience in M&A transactions, venture capital and strategic management.
Prior to joining ATAI, Allan spent several years working in the non-profit healthcare sector, serving as Membership Manager and lead fundraiser at the Coalition to Transform Advanced Care (C-TAC), a membership-based advocacy organization working to reform the Medicare payment system.
Noemi is a Business Operations intern at ATAI Life Sciences AG currently focused on fundraising and investor relations efforts. Before joining ATAI Noemi, has gained first insights into strategic consulting, European governmental affairs, and human resources across various industries and companies including Accenture Strategy, Covestro a Dax30 chemical company, and Audibene a MedTech start-up.
Max de Rosnay
Max recently graduated from the University of Sydney where he completed a B.A of Arts & Science, majoring in Philosophy. Prior to working at ATAI, Max worked as a trade analyst and as a volunteer for charities based in England and Zimbabwe. What got Max interested in the mental health space were his own experiences; from a young age, he struggled with undiagnosed anxiety and depression, which subsequently developed into serious mental illness.